GLP-1 Switch — Semaglutide → Tirzepatide
Transition from semaglutide to tirzepatide — typically for improved efficacy or to access dual GIP/GLP-1 mechanism. Often done after plateau on semaglutide. Most patients experience renewed weight loss momentum after switching.
Duration
—
Steps
10
Total Weeks
32
Route
SubQ
Protocols
2
Source
clinical practice
Protocol Timeline
| Step | Weeks | Dose | Compound | Note |
|---|---|---|---|---|
| 1 | 4 | 0.25 mg | Semaglutide (Injectable) | Initiation dose — for GI tolerability, not therapeutic |
| 2 | 4 | 0.5 mg | Semaglutide (Injectable) | First therapeutic dose |
| 3 | 4 | 1 mg | Semaglutide (Injectable) | Standard target dose — increase if additional glycemic control needed |
| 4 | 0 | 2 mg | Semaglutide (Injectable) | Maximum dose — maintenance |
| 1 | 4 | 2.5 mg | Tirzepatide | Initiation dose — for GI tolerability |
| 2 | 4 | 5 mg | Tirzepatide | First therapeutic dose |
| 3 | 4 | 7.5 mg | Tirzepatide | Increase if additional glycemic control needed |
| 4 | 4 | 10 mg | Tirzepatide | — |
| 5 | 4 | 12.5 mg | Tirzepatide | — |
| 6 | 0 | 15 mg | Tirzepatide | Maximum dose — maintenance |
Rationale
Start tirzepatide at 2.5mg regardless of semaglutide dose — tirzepatide GIP mechanism causes additional GI load. No washout needed. Most patients who switch report stronger appetite suppression within 2–4 weeks.
Compounds Used
Related Tools
Track this regimen in Doseline
Adopt GLP-1 Switch — Semaglutide → Tirzepatide as a template, set reminders for every step, and log doses as you go. All free, all private.
Join the waitlistDoseline provides informational tools only. It is not a medical device and does not provide medical advice. Always consult a qualified healthcare provider.